OpenArc Corporate Advisory, LLC
Position in HALO — Halozyme Therapeutics, Inc.
CIK 2111345
ATLANTA, GA
Position in HALO
as of Jun 30, 2026
· filed Aug 5, 2026
Position Value
$1,589,663
+$297,904 QoQ
Shares Held
20,310
+1.6% QoQ
Ownership
0.018%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
#264
of 669 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in HALO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026OpenArc Corporate Advisory, LLC holds $10,123,972 across 17 Biotechnology names. HALO ranks #2 (15.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TVTX |
Travere Therapeutics, Inc.
|
37,500 | $2,130,375 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
This page
|
20,310 | $1,589,663 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,397 | $1,190,661 | |
| 4 | ARQT |
Arcutis Biotherapeutics, Inc.
|
30,700 | $804,954 | |
| 5 | PBYI |
Puma Biotechnology, Inc.
|
59,491 | $482,472 | |
| 6 | PHVS |
Pharvaris N.V.
|
13,595 | $470,115 | |
| 7 | ARGX |
Argenx SE
|
500 | $463,885 | |
| 8 | REGN |
Regeneron Pharmaceuticals, Inc.
|
688 | $428,995 |
All Filings in HALO
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,589,663 | 20,310 | Shares | Sole | 2026-08-05 | |
| 2026-03-31 | $1,291,759 | 19,987 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $1,299,091 | 19,303 | Shares | Sole | 2026-02-13 | |
| No filing history on record for this holder in this stock. | ||||||